Krebs von den Lungen‐6 (KL‐6) is a high‐molecular‐weight (200kDa) glycoprotein proposed as a diagnostic biomarker for differentiating interstitial lung disease (ILD). Systemic sclerosis (SSc) is a rare immune‐mediated disorder, and… Click to show full abstract
Krebs von den Lungen‐6 (KL‐6) is a high‐molecular‐weight (200kDa) glycoprotein proposed as a diagnostic biomarker for differentiating interstitial lung disease (ILD). Systemic sclerosis (SSc) is a rare immune‐mediated disorder, and ILD is the leading cause of morbidity and mortality. Pleuroparenchymal fibroelastosis (PPFE) has been described to have a poor prognosis in SSc‐ILD patients. This study undertook to compare serial changes in KL‐6 in SSc‐ILD patients with and without PPFE, to verify its prognostic value as a disease biomarker.
               
Click one of the above tabs to view related content.